# Children's Oncology Group (COG)

Source: https://onco.cc/companies/childrens-oncology-group/  
OnCo record `childrens-oncology-group` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Children's Oncology Group is the world's largest paediatric cancer trials organisation; most children with cancer in North America are treated on or according to a COG protocol.

## Summary

The Children's Oncology Group, based in Monrovia, California, is the world's largest paediatric cancer trials organisation, formed in 2000 from four paediatric groups with more than two hundred member hospitals; most children with cancer in North America are treated on or according to a COG protocol. Its trials define risk-adapted therapy: AALL1731 added blinatumomab to chemotherapy for standard-risk B-cell ALL, ANBL0032 established anti-GD2 immunotherapy in neuroblastoma, and AAML0531, ACNS0331 and AHOD2131 cover leukaemia, brain tumours and Hodgkin lymphoma. OnCo connects it to the RACE for Children Act and to bottlenecks on paediatric cancers without markets and neglected late effects. Whether every treated child can be followed for decades through registry linkage is the open idea. Its programmes are listed in the notes.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- Also known as: Children's Oncology Group; COG
- Tags: cooperative-group
- HQ: Monrovia, CA
- Type: cooperative-group
- Website: https://childrensoncologygroup.org

## Notes

- Paediatric ALL (AALL trials)
- Neuroblastoma (ANBL trials)
- Survivorship

## Sources

- Official website: https://childrensoncologygroup.org

## Connected records

- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia in children](https://onco.cc/cancers/aml-paediatric/), [Adolescent and young adult cancers (ages 15 to 39)](https://onco.cc/cancers/aya-cancers/), [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Atypical teratoid/rhabdoid tumour (ATRT)](https://onco.cc/cancers/atrt/), [Burkitt lymphoma](https://onco.cc/cancers/burkitt-lymphoma/), [Central nervous system germ cell tumours (germinoma and non-germinomatous)](https://onco.cc/cancers/cns-germ-cell-tumours/), [Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)](https://onco.cc/cancers/pleuropulmonary-blastoma/), [Craniopharyngioma](https://onco.cc/cancers/craniopharyngioma/), [Diffuse midline glioma, H3 K27-altered (including DIPG)](https://onco.cc/cancers/dipg-dmg/), [Early-stage classical Hodgkin lymphoma (stage I to II)](https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/), [Ependymoma](https://onco.cc/cancers/ependymoma/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Germ cell tumours of childhood and adolescence (extracranial and CNS)](https://onco.cc/cancers/paediatric-germ-cell-tumours/), [Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)](https://onco.cc/cancers/medulloblastoma-group-3-4/), [Hepatoblastoma](https://onco.cc/cancers/hepatoblastoma/), [High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)](https://onco.cc/cancers/all-paediatric-high-risk/), [High-risk neuroblastoma](https://onco.cc/cancers/neuroblastoma-high-risk/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Inflammatory myofibroblastic tumour (IMT)](https://onco.cc/cancers/inflammatory-myofibroblastic-tumour/), [Intermediate-risk neuroblastoma](https://onco.cc/cancers/neuroblastoma-intermediate-risk/), [Langerhans cell histiocytosis (LCH)](https://onco.cc/cancers/langerhans-cell-histiocytosis/), [Low-risk neuroblastoma (INRG very low and low risk, including stage MS)](https://onco.cc/cancers/neuroblastoma-low-risk/), [Medulloblastoma](https://onco.cc/cancers/medulloblastoma/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)](https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/), [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/), [Paediatric high-grade glioma (excluding diffuse midline glioma)](https://onco.cc/cancers/paediatric-high-grade-glioma/), [Paediatric low-grade glioma](https://onco.cc/cancers/paediatric-low-grade-glioma/), [Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)](https://onco.cc/cancers/all-ph-like/), [Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)](https://onco.cc/cancers/all-paediatric-ph-positive/), [Rare cancers of childhood (NCI PDQ umbrella)](https://onco.cc/cancers/rare-childhood-cancers/), [Relapsed and refractory acute lymphoblastic leukaemia in children](https://onco.cc/cancers/all-paediatric-relapsed/), [Retinoblastoma](https://onco.cc/cancers/retinoblastoma/), [Rhabdomyosarcoma](https://onco.cc/cancers/rhabdomyosarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [SHH-activated medulloblastoma](https://onco.cc/cancers/medulloblastoma-shh/), [Standard-risk B-cell acute lymphoblastic leukaemia in children](https://onco.cc/cancers/all-paediatric-standard-risk/), [Wilms tumour (nephroblastoma)](https://onco.cc/cancers/wilms-tumor/), [WNT-activated medulloblastoma](https://onco.cc/cancers/medulloblastoma-wnt/)
- institutions: [Children's Cancer Hospital Egypt 57357](https://onco.cc/institutions/cche-57357/), [Children's Hospital of Philadelphia](https://onco.cc/institutions/chop/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [Nationwide Children's Hospital](https://onco.cc/institutions/nationwide-childrens/), [SIOP Europe (European Society for Paediatric Oncology)](https://onco.cc/institutions/siop-europe/), [St. Jude Children's Research Hospital](https://onco.cc/institutions/st-jude/), [Sydney Children's Hospitals Network / Children's Cancer Institute](https://onco.cc/institutions/sydney-childrens-hospitals-network/), [Texas Children's Cancer and Hematology Center](https://onco.cc/institutions/texas-childrens/), [The Hospital for Sick Children (SickKids)](https://onco.cc/institutions/sickkids/), [UC San Diego Moores Cancer Center](https://onco.cc/institutions/ucsd-moores/), [University of Wisconsin Carbone Cancer Center](https://onco.cc/institutions/uw-carbone/)
- people: [Alice L. Yu](https://onco.cc/people/alice-yu/), [Douglas S. Hawkins](https://onco.cc/people/douglas-hawkins/), [Julie R. Park](https://onco.cc/people/julie-park/), [Katherine K. Matthay](https://onco.cc/people/katherine-matthay/), [Rachel E. Rau](https://onco.cc/people/rachel-rau/), [Susan L. Cohn](https://onco.cc/people/susan-cohn/)
- trials: [AALL0232](https://onco.cc/trials/aall0232/), [AALL1231](https://onco.cc/trials/aall1231/), [AALL1331](https://onco.cc/trials/aall1331/), [AALL1521](https://onco.cc/trials/aall1521/), [AAML1031](https://onco.cc/trials/aaml1031/), [ACNS0121](https://onco.cc/trials/acns0121/), [ACNS0122](https://onco.cc/trials/acns0122/), [ACNS0333](https://onco.cc/trials/acns0333/), [ACNS1123](https://onco.cc/trials/acns1123/), [ACNS1422](https://onco.cc/trials/acns1422/), [AEWS0031](https://onco.cc/trials/aews0031/), [AGCT1531](https://onco.cc/trials/agct1531/), [AHOD1331](https://onco.cc/trials/ahod1331/), [AHOD2131 (COG / NCTN)](https://onco.cc/trials/ahod2131/), [ANBL0531](https://onco.cc/trials/anbl0531/), [ANBL1221](https://onco.cc/trials/anbl1221/), [ANBL17P1](https://onco.cc/trials/anbl17p1/), [COG AALL1731](https://onco.cc/trials/aall1731/), [COG AAML0531](https://onco.cc/trials/aaml0531/), [COG ACNS0331](https://onco.cc/trials/acns0331/), [COG ANBL0032](https://onco.cc/trials/anbl0032/), [COG ANBL0532](https://onco.cc/trials/anbl0532/), [COG ANBL1531](https://onco.cc/trials/anbl1531/), [COG AREN0533](https://onco.cc/trials/aren0533/), [EURAMOS-1](https://onco.cc/trials/euramos-1/), [INT-0091 (Ewing sarcoma)](https://onco.cc/trials/int-0091/), [Inter-B-NHL Ritux 2010](https://onco.cc/trials/inter-b-nhl-ritux-2010/), [NCI-COG Pediatric MATCH (APEC1621)](https://onco.cc/trials/pediatric-match/), [SWOG S1826](https://onco.cc/trials/swog-s1826/)
- bottlenecks: [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)
- ideas: [Advance market commitments for paediatric and rare cancer drugs](https://onco.cc/ideas/idea-fund-amc-paediatric-rare/), [An international consortium pooling the outcome of every treated child with cancer](https://onco.cc/ideas/idea-data-paediatric-rwe-consortium/), [Develop drugs in children first when the target is a children's target](https://onco.cc/ideas/idea-bio2-paediatric-first-development/), [Escrow a share of adult revenue until the paediatric study is done](https://onco.cc/ideas/idea-fund-paediatric-deferral-escrow/), [Follow every trial participant for 30 years through registry linkage](https://onco.cc/ideas/idea-data-registry-follow-up-of-trial-participants/), [Inhaled immune therapy to make the lung hostile to arriving tumour cells](https://onco.cc/ideas/idea-bio2-inhaled-lung-niche-immunotherapy/), [Make paediatric combination studies part of every relevant adult cancer drug approval](https://onco.cc/ideas/idea-tr2-paediatric-combo-prea/)
- technologies: [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/)
- collections: [Alex's Lemonade Stand Foundation (ALSF)](https://onco.cc/collections/alexs-lemonade-stand/), [St. Baldrick's Foundation](https://onco.cc/collections/st-baldricks/)
- key papers: [Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL](https://onco.cc/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/), [SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults](https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/)
- terms: [RACE for Children Act](https://onco.cc/terms/race-for-children-act/)
- roadmaps: [Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first](https://onco.cc/roadmaps/paediatric-oncology-roadmap/), [Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on](https://onco.cc/roadmaps/trial-modernisation-roadmap/)
- companies: [Children's Cancer and Leukaemia Group](https://onco.cc/companies/cclg/)

---
JSON: https://onco.cc/api/v1/entities/childrens-oncology-group.json